PDF herunterladen
J Pediatr Infect Dis 2019; 14(03): 103-107
DOI: 10.1055/s-0038-1675582
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Tigecycline Use in Neonates: 5-Year Experience of a Tertiary Center

Mehmet Sah İpek
1   Division of Neonatology, Department of Pediatrics, Memorial Dicle Hospital, Diyarbakir, Turkey
,
Mehmet Emin Gunel
2   Department of Pediatrics, Memorial Dicle Hospital, Diyarbakir, Turkey
,
Erdal Ozbek
3   Department of Microbiology, Diyarbakir Maternity and Children Hospital, Diyarbakir, Turkey
› Institutsangaben
Weitere Informationen

Publikationsverlauf

25. März 2018

26. September 2018

Publikationsdatum:
09. November 2018 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

The off-label use of tigecycline to treat serious infections has been reported in pediatric patients. We report four newborn infants diagnosed with sepsis caused by extensively drug-resistant Klebsiella pneumoniae and successfully treated with tigecycline. If no alternative drugs are available, tigecycline may be considered as an option for nosocomial infections even in newborn infants. However, further reports are needed to establish its efficacy and safety.

Keywords

tigecycline - neonate - infection - thrombocytopenia
 

  • References

  • 1 Mastrolia MV, Galli L, De Martino M, Chiappini E. Use of tigecycline in pediatric clinical practice. Expert Rev Anti Infect Ther 2017; 15 (06) 605-612
    CrossrefPubMedSuche in Google Scholar
  • 2 Tygacil: FDA full prescribing information. June 1, 2016. Available at: http://www.fda.gov . Accessed December 15, 2017
    PubMed
  • 3 Iosifidis E, Violaki A, Michalopoulou E. , et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatric Infect Dis Soc 2017; 6 (02) 123-128
    CrossrefPubMedSuche in Google Scholar
  • 4 Hurtado IC, Trujillo M, Restrepo A, Garcés C, Tamayo C, Mesa JG. Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae [Article in Spanish]. Rev Chilena Infectol 2012; 29 (03) 317-321
    CrossrefPubMedSuche in Google Scholar
  • 5 Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr 2016; 105 (10) e480-e484
    CrossrefPubMedSuche in Google Scholar
  • 6 Prot-Labarthe S, Youdaren R, Benkerrou M, Basmaci R, Lorrot M. Pediatric acute pancreatitis related to tigecycline. Pediatr Infect Dis J 2010; 29 (09) 890-891
    PubMedSuche in Google Scholar
  • 7 Emiroglu M, Alkan G, Turk Dagi H. Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics 2017; 139 (01) 139
    Suche in Google Scholar
  • 8 Purdy J, Jouve S, Yan JL. , et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34 (02) 496-507.e1
    CrossrefPubMedSuche in Google Scholar
  • 9 Magiorakos AP, Srinivasan A, Carey RB. , et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18 (03) 268-281
    CrossrefPubMedSuche in Google Scholar
  • 10 Zeng J, Zhang L, Gao M. , et al. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia. Int J Infect Dis 2017; 61: 23-26
    CrossrefPubMedSuche in Google Scholar
  • 11 Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57 (04) 1756-1762
    CrossrefPubMedSuche in Google Scholar
  • 12 Ni W, Han Y, Liu J. , et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (11) e3126
    PubMedSuche in Google Scholar
  • 13 Daikos GL, Tsaousi S, Tzouvelekis LS. , et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (04) 2322-2328
    CrossrefPubMedSuche in Google Scholar
  • 14 Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F. , et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015; 70 (03) 905-913
    CrossrefPubMedSuche in Google Scholar
  • 15 Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H. Conventional versus prolonged infusion of meropenem in neonates with gram-negative late-onset sepsis: a randomized controlled trial. Pediatr Infect Dis J 2017; 36 (04) 358-363
    CrossrefPubMedSuche in Google Scholar
  • 16 Eckmann C, Heizmann W, Bodmann KF, von Eiff C, Petrik C, Loeschmann PA. Tigecycline in the treatment of patients with necrotizing skin and soft tissue infections due to multiresistant bacteria. Surg Infect (Larchmt) 2015; 16 (05) 618-625
    CrossrefPubMedSuche in Google Scholar
  • 17 Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133 (02) 309-314
    CrossrefPubMedSuche in Google Scholar
  • 18 İpek MS, Aktar F, Okur N, Celik M, Ozbek E. Colistin use in critically ill neonates: a case-control study. Pediatr Neonatol 2017; 58 (06) 490-496
    CrossrefPubMedSuche in Google Scholar